2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

508. Bone Marrow Failure: Acquired: Poster III

Program: Poster Abstract Session
Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Treatment Considerations, Combination Therapy, Drug Development, Therapy Sequence, Non-Biological Therapies, Chemotherapy, Pharmacology, Adverse Events, Biological Processes, Pathogenesis, CHIP, Hematopoiesis, Immune Mechanism, Diseases, Bone Marrow Failure Syndromes, Acquired Marrow Failure Syndromes , Inherited Marrow Failure Syndromes, Aplastic Anemia, Paroxysmal Nocturnal Hemoglobinuria, Genetic Disorders, Immunology, Autoimmune Disorders, Immunodeficiency, Lymphoid Malignancies, Lymphoid Leukemias, Plasma Cell Disorders, LGL, Research, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Patient-Reported Outcomes, Real-World Evidence, Registries, Study Population, Human, Adult, Elderly, Pediatric, Young Adult
PAPER

4927 Cross-population comparison of aplastic anemia genome-wide association studies identifies candidate genes in the east Asian population

Zhongshan Cheng, PhD, Shaohua Lei, PhD2, Ti-Cheng Chang, PhD, MSc3
1 Saint Jude Children's Research Hospital, Memphis, Tennessee, United States
2 Saint Jude Children's Research Hospital, Memphis, Tennessee, United States
3 Saint Jude Children's Research Hospital, Memphis, Tennessee, United States

Background

Aplastic anemia (AA) is a rare, life-threatening bone marrow failure disorder characterized by hypocellular marrow and peripheral-blood cytopenias (Young 2018). Although immune-mediated destruction of hematopoietic stem and progenitor cells is central to acquired AA (Keohane 2004, Wu, Gao et al. 2025), variation in disease incidence and clinical presentation suggests genetic factors predisposing to AA (Young 2018). However, AA genetic studies across populations are limited, as most AA genome-wide association studies (GWASs) were conducted in European (EUR) populations (Savage, Viard et al. 2020, Laisk, Lepamets et al. 2021) and no replicable AA loci have been reported in East Asian (EAS) population so far.

Methods

We analyzed publicly available AA GWAS summary statistics from a previous study (Sakaue, Kanai et al. 2021), comprising 4,128 EUR cases and 469,372 controls and 53 EAS cases (predominantly from Japan) and 174,057 controls, for which only the EAS and EAS+EUR GWAS summary statistics of AA were accessible. The two GWASs were harmonized, adjusted for sample overlap, compared ancestry-stratified effect estimates, calculated pairwise differential statistics, and prioritized variants with minor allele frequency greater than 5% according to (Cheng, Cai et al. 2023). Variants were prioritized based on differential-association strength, evidence of association within the individual GWAS datasets, and direction of effect. Functional annotations of lead variants and ancestry-matched proxies in linkage disequilibrium (LD) (R2≥0.8) were evaluated using HaploReg v4.2 (Ward and Kellis 2012).

Results

Forty-seven variants met the standardized differential-association threshold (P_std-diff<5×10⁻⁸). Most showed stronger association evidence in the EAS dataset, with its original association P values ranging from 3.2×10-6 to 3×10-4 and 0.03 to 0.9 for EAS and EAS+EUR GWASs, respectively; however, this pattern must be interpreted in the context of the approximately 79-fold difference in case numbers between the EAS+EUR and EAS analyses, as well as the complete covering of EAS samples by the former dataset, strongly suggesting that manual prioritization of these variants is necessary.

The top standardized differential signal was rs58750654, adjacent to a pseudogene, LOC1720 (P_std-diff=3.01×10-11), which was suggestively significant in EAS (P_EAS=3.2×10-6) but showed no evidence of association in EAS+EUR. The potential involvement of LOC1720 is unclear, as its function has not been investigated. Variant rs3904003, close to PCDH9, showed opposite estimated effects and nominal association in both GWASs (β_EAS+EUR=0.049, P_EAS+EUR=0.030; β_EAS=−0.704, P_EAS=2.04×10⁻⁴; P_std-diff=8.37×10⁻⁹). However, the SNP is not an expression quantitative-trait locus (eQTL) of PCDH9, which is a psychiatric disease gene (Xiao, Zheng et al. 2018), against its potential involvement in AA. Other variants were also manually evaluated but without relevance to AA from literature. We thus relaxed the screening threshold to obtain five additional variants, including rs9685465, rs67594385, rs4747251, rs7147849, and rs76084479, that showed differential effect sizes (P_std-diff<1×10-6) with nominal evidence in both datasets.

Functional annotation prioritized rs67594385, an intronic variant in C7orf50/CHLSN (Hu, Chen et al. 2024) (related to cholesterol metabolism) that overlapped regulatory annotations in hematopoietic and immune cells and had PAX5-binding motif and lymphoblastoid exon-level eQTL evidence. Additional annotations supported KLHL2 (tagged by rs9685465) (Takahashi, Mori et al. 2013), the protein of which interacts with and ubiquitinates WNK kinases, BCL11B (a master regulator in the immune, hematopoietic, and nervous systems) (García-Aznar, Alonso Alvarez et al. 2024) adjacent to rs7147849 with its high LD SNP rs807438 (R2=0.91 in EUR) a trans-eQTL of RASD1 (Zeller, Wild et al. 2010), whose reduced expression correlated with anemia in multiple myeloma (Yi, Ren et al. 2026), and COL13A1 (involved in bone homeostasis) (Kemppainen, Finnilä et al. 2022) linked to rs76084479.

Conclusions

Cross-population comparison of AA GWASs identified candidate variants with heterogeneous association signals between EUR and EAS populations. The findings prioritize five loci, including CHLSN, KLHL2, BCL11B/RASD1, and COL13A1 for further investigation in the EAS population.

Zhongshan Cheng, PhD: No relevant conflicts of interest to declare.